Page last updated: 2024-12-06

castanospermine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Castanospermine is a natural alkaloid isolated from the seeds of the Australian chestnut tree (Castanospermum australe). It is a potent inhibitor of α-glucosidase, an enzyme that breaks down complex carbohydrates into simple sugars. This inhibition leads to a reduction in glucose absorption, making castanospermine a potential therapeutic agent for the treatment of diabetes. Castanospermine is also a potent inhibitor of viral enzymes, including HIV reverse transcriptase and influenza neuraminidase. This makes it a potential antiviral drug. Castanospermine has been studied extensively for its potential therapeutic applications in a variety of diseases, including diabetes, HIV/AIDS, and cancer. Its unique chemical structure and biological activity make it a valuable tool for researchers investigating the development of new drugs.'

castanospermine: indolizidine alkaloid from seeds of Australian legume, Castanospermum australe [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

castanospermine : A tetrahydroxyindolizidine alkaloid that consists of octahydroindolizine having four hydroxy substituents located at positions 1, 6, 7 and 8 (the 1S,6S,7R,8R,8aR-diastereomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
CastanospermumgenusA plant genus of the family FABACEAE that contains castanospermines, swainsonine, and triterpenoid saponins.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]
Castanospermum australespecies[no description available]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]
Castanospermum australespecies[no description available]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID54445
CHEMBL ID311226
CHEBI ID27860
SCHEMBL ID61040
MeSH IDM0114165

Synonyms (83)

Synonym
chebi:27860 ,
CHEMBL311226
HMS3266B08
nsc-625381
smr000059227
MLS000028641
6-epicastanospermine
nsc 625381
castinospermine
cid54445
BIO1_000396
BIO1_001374
BIO2_000272
BIO1_000885
BIO2_000752
IDI1_034022
BCBCMAP01_000133
SMP1_000059
(1s,6s,7r,8r,8ar)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,6,7,8-tetrol
indolizine der.
(1s,6s,7r,8r,8ar)-1,6,7,8-tetrahydroxyindolizidine
cast
nsc625381
CTS ,
UPCMLD-DP122:002
UPCMLD-DP122:001
castanospermine
C02256
79831-76-8
castanospermine, >=94% (gc), bioultra, from castanospermum australe seeds
(1s,6s,7r,8r,8ar)-1,6,7,8-tetrahydroxyindolizidine, 98%
DB01816
1,6,7,8-tetrahydroxyoctahydroindolizine
UPCMLD-DP122
(1s-(1alpha,6beta,7alpha,8beta,8alphabeta))-octahydro-1,6,7,8-indolizinetetrol
2CBU
UPCMLD-DP122:003
NCGC00024773-02
KBIOSS_000272
KBIO3_000544
KBIO2_005408
MOLMAP_000013
KBIOGR_000272
KBIO3_000543
KBIO2_002840
KBIO2_000272
BSPBIO_001552
NCGC00024773-04
HMS1989N14
81041B9A-D148-44DC-A86D-C78D6ABF9633
HMS1791N14
HMS1361N14
unii-q0i3184xm7
1,6,7,8-indolizinetetrol, octahydro-, (1s-(1alpha,6beta,7alpha,8beta,8abeta))-
q0i3184xm7 ,
octahydro-indolizine-1,6,7,8-tetraol, 13
bdbm36388
HMS2232G11
(1s,6s,7r,8r,8ar)-octahydro-1,6,7,8-indolizinetetrol
(1s,6s,7r,8r,8ar)-octahydroindolizine-1,6,7,8-tetrol
castanospermine [mi]
CCG-208170
SCHEMBL61040
JDVVGAQPNNXQDW-TVNFTVLESA-N
W-203822
[1s-(1?,6?,7?,8?,8a?)]-octahydro-1,6,7,8-indolizinetetrol
AKOS024458634
HMS3402N14
mfcd00017555
HY-N2022
SR-01000597675-4
sr-01000597675
SR-01000597675-1
CS-5633
castanospermine from castanospermum australe seeds
HMS3678H05
(1s,6s,7r,8r,8ar)-octahydroindolizine-1,6,7,8-tetraol
HMS3414H05
Q753104
79831-76-8 (free base)
DTXSID601026043
1,6,7,8-indolizinetetrol, octahydro-,?(1s,6s,7r,8r,8ar)-
EN300-7407999

Research Excerpts

Overview

Castanospermine (CAST) is an alkaloid from the Castanospermum australe, known as an anti-inflammatory agent and immunosuppressant in animal experiments. Castanos permine is a potent inhibitor of various alpha-glucosidases in eukaryotes.

ExcerptReferenceRelevance
"Castanospermine (CAST) is an alkaloid from the Castanospermum australe, known as an anti-inflammatory agent and immunosuppressant in animal experiments."( Effects of Castanospermine on Inflammatory Response in a Rat Model of Experimental Severe Acute Pancreatitis.
Chen, C; Guo, WY; Hong, YP; Mei, FC; Wang, WX; Xiang, MW; Zhao, L, 2016
)
1.55
"Castanospermine proved to be a competitive inhibitor of amyloglucosidase at both pH 4.5 and 6.0 when assayed with the p-nitrophenyl-alpha-D-glucoside."( Studies on the mechanism of castanospermine inhibition of alpha- and beta-glucosidases.
Elbein, AD; Molyneux, RJ; Saul, R, 1984
)
1.28
"Castanospermine is an indolizidine alkaloid that is found in the seeds of the Australian tree Castanospermum australe. "( The effects of castanospermine and swainsonine on the activity and synthesis of intestinal sucrase.
Elbein, AD; Ghidoni, J; Pan, YT, 1993
)
2.08
"Castanospermine (CAST) is a known and potent inhibitor of various alpha-glucosidases in eukaryotes. "( Inhibition of bacterial alpha-glucosidases by castanospermine in pure cultures and activated sludge.
Mustafa, N; Sörensson, F; Thörn, M, 2002
)
2.02
"Castanospermine is a quasi-irreversible sucrase inhibitor that did not dissociate from sucrase during tissue preparation or assay for sucrase activity."( Quantitative relationship between intestinal sucrase inhibition and reduction of the glycemic response to sucrose in rats.
Begovic, ME; Heineke, EW; Robinson, KM, 1990
)
1
"Castanospermine (CS) is a potent but non-selective inhibitor of many glycohydrolases including the intestinal disaccharidases. "( Castanospermine-glucosides as selective disaccharidase inhibitors.
King, CH; Liu, PS; Rhinehart, BL; Robinson, KM, 1990
)
3.16
"6-Epicastanospermine was found to be a potent inhibitor of amyloglucosidase, (an exo-1,4-alpha-glucosidase), a weak inhibitor of beta-galactosidase, and not to inhibit beta-glucosidase and alpha-mannosidase."( 6-Epicastanospermine, a novel indolizidine alkaloid that inhibits alpha-glucosidase.
Dunnheim, G; Elbein, AD; Molyneux, RJ; Roitman, JN; Szumilo, T, 1986
)
1.24
"Castanospermine is a potent inhibitor of rat hepatic lysosomal alpha-glucosidase in vitro. "( Castanospermine: an apparent tight-binding inhibitor of hepatic lysosomal alpha-glucosidase.
Ellmers, BR; Rhinehart, BL; Robinson, KM, 1987
)
3.16
"Castanospermine is a potent inhibitor of rat intestinal glycohydrolases in vitro and prevents the hyperglycemic response to an oral sucrose challenge in vivo. "( Castanospermine blocks the hyperglycemic response to carbohydrates in vivo: a result of intestinal disaccharidase inhibition.
Cheng, W; Fisher, JL; Liu, PS; Payne, AJ; Rhinehart, BL; Robinson, KM; Wheatley, ME, 1987
)
3.16

Effects

Castanospermine has been shown to inhibit tumor growth and metastasis in mouse and rat models. It inhibits homogeneously glycan maturation in sycamore cells and leads to the accumulation of a single immature N-glycan.

ExcerptReferenceRelevance
"Castanospermine has a prolonged duration of activity in vivo with significant activity when administered 4 hours before sucrose."( Castanospermine blocks the hyperglycemic response to carbohydrates in vivo: a result of intestinal disaccharidase inhibition.
Cheng, W; Fisher, JL; Liu, PS; Payne, AJ; Rhinehart, BL; Robinson, KM; Wheatley, ME, 1987
)
2.44
"Castanospermine has been selected because it inhibits homogeneously glycan maturation in sycamore cells and leads to the accumulation of a single immature N-glycan."( N-linked oligosaccharide processing is not necessary for glycoprotein secretion in plants.
Avidgor, V; Chekkafi, A; Faye, L; Fichette-Lainé, AC; Lerouge, P, 1996
)
1.02
"Castanospermine has been shown to inhibit tumor growth and metastasis in mouse and rat models."( The effect of castanospermine on the metastatic properties of prostate cancer cells.
Lehr, JE; Pienta, KJ; Quigley, M; Schwab, ED; Yee, CS,
)
1.21
"Castanospermine has a prolonged duration of activity in vivo with significant activity when administered 4 hours before sucrose."( Castanospermine blocks the hyperglycemic response to carbohydrates in vivo: a result of intestinal disaccharidase inhibition.
Cheng, W; Fisher, JL; Liu, PS; Payne, AJ; Rhinehart, BL; Robinson, KM; Wheatley, ME, 1987
)
2.44

Actions

Castanospermine is shown to inhibit syncytium formation induced by the envelope glycoprotein of the human immunodeficiency virus and to inhibit viral replication. It did not inhibit the incorporation of [3H]leucine or [14C]alanine into protein in MDCK cells at levels as high as 50 micrograms/mL.

ExcerptReferenceRelevance
"Castanospermine did not inhibit the incorporation of [3H]leucine or [14C]alanine into protein in MDCK cells at levels as high as 50 micrograms/mL."( Castanospermine inhibits the processing of the oligosaccharide portion of the influenza viral hemagglutinin.
Elbein, AD; Hori, H; Molyneux, RJ; Pan, YT; Sanford, BA; Saul, R, 1983
)
2.43
"Castanospermine was used to inhibit processing of N-linked glycoproteins by its inhibitory action on glucosidase I, the enzyme responsible for the initial trimming of glucose residues from the glucosylated high mannose core oligosaccharide derived from the dolichol pathway."( Glycoprotein processing is required for completion but not initiation of oligodendroglial differentiation from its bipotential progenitor cell.
Ishii, S; Volpe, JJ, 1992
)
1
"Castanospermine could also inhibit inflammation through its ability to prevent the expression of adhesion molecules, which may be necessary for the capture and retention of leucocytes in the inflamed tissue."( Inhibition of adjuvant arthritis in the rat by phosphosugars and the alpha-glucosidase inhibitor castanospermine.
Cowden, WB; Parish, CR; Willenborg, DO, 1992
)
1.22
"Castanospermine caused an increase in 'abnormal', apparently glucosylated high mannose structures and a decrease in all other 'normal' high mannose oligosaccharides, whereas DMM caused an increase in most high mannose structures, especially those migrating in the region of the Man7GlcNAc standard."( Specific N-linked oligosaccharides are required for oligodendroglial differentiation but probably not for astrocytic differentiation.
Ishii, S; Volpe, JJ, 1990
)
1
"Castanospermine is shown to inhibit syncytium formation induced by the envelope glycoprotein of the human immunodeficiency virus and to inhibit viral replication."( Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine.
Goh, WC; Haseltine, WA; Kowalski, M; Kozarsky, K; Krieger, M; Rohrschneider, L; Rosen, C; Sodroski, J; Walker, BD, 1987
)
1.22

Treatment

The castanospermine-treated GnT-III was not localized in the Golgi, but glucosylation did not affect its activity. The cells contained smaller numbers of cisternae in each Golgi stack; much larger numbers of secretory vesicles.

ExcerptReferenceRelevance
"The castanospermine-treated GnT-III was not localized in the Golgi, but glucosylation did not affect its activity."( N-glycosylation is requisite for the enzyme activity and Golgi retention of N-acetylglucosaminyltransferase III.
Ihara, Y; Nagai, K; Taniguchi, N; Wada, Y, 1997
)
0.78
"Castanospermine treatment reduces the association of calnexin with the alpha-subunit of the receptor, and diminishes the intracellular accumulation of unassembled receptor subunit protein."( Inhibition of glucose trimming with castanospermine reduces calnexin association and promotes proteasome degradation of the alpha-subunit of the nicotinic acetylcholine receptor.
Keller, SH; Lindstrom, J; Taylor, P, 1998
)
1.3
"The castanospermine-treated cells contained smaller numbers of cisternae in each Golgi stack; much larger numbers of secretory vesicles which were also substantially larger in size and four times as many coated vesicles per section as control cells."( The effect of castanospermine on embryonic mouse cerebellar neurons in culture.
Bird, MM, 1999
)
1.14
"Castanospermine treatment after calnexin binding blocked the dissociation of the chaperone but still caused accelerated degradation."( Differential role of mannose and glucose trimming in the ER degradation of asialoglycoprotein receptor subunits.
Ayalon-Soffer, M; Lederkremer, GZ; Shenkman, M, 1999
)
1.02
"Castanospermine treatment of infected astrocytes, which blocks glucose trimming from oligosaccharide side chains of glycoproteins, both obliterated the mobility difference between astrocyte- and CrFK-produced FIV surface glycoproteins and prevented syncytium in infected astrocyte cultures."( Cell-specific envelope glycosylation distinguishes FIV glycoproteins produced in cytopathically and noncytopathically infected cells.
Dow, SW; Hoover, EA; Poss, ML, 1992
)
1
"Castanospermine treatment of 61E-infected 3201 T cells, however, not only abrogated the antigenic differences between the 61E and EECC glycoproteins but also resulted in a cytopathic effect."( Characterization and significance of delayed processing of the feline leukemia virus FeLV-FAIDS envelope glycoprotein.
Hoover, EA; Mullins, JI; Poss, ML; Quackenbush, SL, 1990
)
1
"Castanospermine-treated SM-FRE (v-fms transformed) cells reexpressed extracellular matrix fibronectin and exhibited an extensive actin-containing cytoskeleton similar to that of normal nontransformed FRE cells."( Transformation by the oncogene v-fms: the effects of castanospermine on transformation-related parameters.
Hakomori, SI; Manger, R; Nichols, EJ; Rohrschneider, LR, 1987
)
1.24
"Treatment with castanospermine does not alter the tyrosine kinase autophosphorylation activity of any of the v-sea products, and the synthesis and processing of p38 is unaffected."( Abnormal glycosylation of the env-sea oncogene product inhibits its proteolytic cleavage and blocks its transforming ability.
Beug, H; Hayman, MJ; Knight, J; Marshall, J, 1988
)
0.61

Dosage Studied

ExcerptRelevanceReference
" The single-channel conductance was not altered by any of the three inhibitors, and the slopes of log-log dose-response curves at low concentrations and desensitization did not appear to be affected."( Inhibitors of asparagine-linked oligosaccharide processing alter the kinetics of the nicotinic acetylcholine receptor.
Covarrubias, M; Kopta, C; Steinbach, JH, 1989
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
anti-HIV-1 agentAn anti-HIV agent that destroys or inhibits the replication of HIV-1, the more infective and more virulent of the two types of HIV virus.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
EC 3.2.1.* (glycosidase) inhibitorAn EC 3.2.* (glycosylase) inhibitor that interferes with the action of any glycosidase (i.e. enzymes hydrolysing O- and S-glycosyl compounds, EC 3.2.1.*).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
indolizidine alkaloid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
vicianin bioactivation113

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glucocerebrosidaseHomo sapiens (human)Potency14.12540.01268.156944.6684AID2101
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency4.97170.036619.637650.1187AID1466; AID2100; AID2112; AID2113; AID2242
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency44.66843.548119.542744.6684AID743266
gemininHomo sapiens (human)Potency23.10930.004611.374133.4983AID624296
DNA polymerase kappa isoform 1Homo sapiens (human)Potency39.81070.031622.3146100.0000AID588579
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency11.22023.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency11.22023.548118.039535.4813AID1466
TAR DNA-binding protein 43Homo sapiens (human)Potency0.35481.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Non-lysosomal glucosylceramidaseHomo sapiens (human)IC50 (µMol)19.00000.00030.08970.3000AID731617
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (33)

Processvia Protein(s)Taxonomy
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
protein foldingPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
glycoprotein catabolic processPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
protein deglycosylationPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
carbohydrate metabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
glucosylceramide catabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
cholesterol metabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
bile acid metabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
glycoside catabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
central nervous system neuron developmentNon-lysosomal glucosylceramidaseHomo sapiens (human)
lipid glycosylationNon-lysosomal glucosylceramidaseHomo sapiens (human)
regulation of actin filament polymerizationNon-lysosomal glucosylceramidaseHomo sapiens (human)
regulation of microtubule polymerizationNon-lysosomal glucosylceramidaseHomo sapiens (human)
glycosphingolipid catabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
regulation of membrane lipid distributionNon-lysosomal glucosylceramidaseHomo sapiens (human)
central nervous system developmentNon-lysosomal glucosylceramidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase activityPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
protein bindingPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
metal ion bindingPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
galactosylceramidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
glucosylceramidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
beta-glucosidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
glucosyltransferase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
steryl-beta-glucosidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
cytosolPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
cytosolPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
nucleusPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
Golgi membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
endoplasmic reticulum membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
smooth endoplasmic reticulumNon-lysosomal glucosylceramidaseHomo sapiens (human)
cytosolNon-lysosomal glucosylceramidaseHomo sapiens (human)
plasma membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (45)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID324396Induction of light chain 3-GFP level in human H4 cells at 13.2 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID501842Inhibition of rat liver glucosidase 2 assessed as inhibition of conversion of G1M9 to M92010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
The action of bromoconduritol on ER glucosidase II.
AID1251299Inhibition of almond beta-glucosidase2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Quaternary Indolizidine and Indolizidone Iminosugars as Potential Immunostimulating and Glycosidase Inhibitory Agents: Synthesis, Conformational Analysis, Biological Activity, and Molecular Docking Study.
AID501841Inhibition of rat liver glucosidase 2 assessed as inhibition of conversion of G2M9 to G1M92010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
The action of bromoconduritol on ER glucosidase II.
AID324448Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 13.2 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID324583Increase in long-lived protein degradation in human H4 cells after 2 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID617947Inhibition of lysosomal alpha-glucosidase2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and glycosidase inhibitory profiles of functionalised morpholines and oxazepanes.
AID324584Increase in long-lived protein degradation in human H4 cells after 4 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID400362Antihyperglycemic effect in STZ-diabetic ddY mouse assessed as reduction in blood glucose level at 150 umol/kg, ip after 4 to 6 hrs by glucose oxidase method1998Journal of natural products, Mar, Volume: 61, Issue:3
Antihyperglycemic effects of N-containing sugars from Xanthocercis zambesiaca, Morus bombycis, Aglaonema treubii, and Castanospermum australe in streptozotocin-diabetic mice.
AID617948Inhibition of lysosomal beta-glucosidase2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and glycosidase inhibitory profiles of functionalised morpholines and oxazepanes.
AID324580Decrease in FYVE-RFP+ vesicle intensity per cell in human H4 cells after 4 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID324581Decrease in FYVE-RFP+ vesicle intensity per cell in human H4 cells after 8 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID324585Increase in long-lived protein degradation in human H4 cells after 24 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1631441Antiviral activity against Dengue virus 2 3295 infected in BHK21 cells after 48 hrs by CFI assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
The Medicinal Chemistry of Dengue Virus.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID497872Inhibition of wild type Bacteroides thetaiotaomicron beta-mannosidase 2A expressed in Escherichia coli BL21 (DE3) at 37 degC and Ph 5.6 by 2,4-dinitrophenolate release assay2008Nature chemical biology, May, Volume: 4, Issue:5
Structural and biochemical evidence for a boat-like transition state in beta-mannosidases.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID335625Inhibition of Aspergillus niger amyloglucosidase by competitive inhibition-based kinetic assay
AID324582Increase in long-lived protein degradation in human H4 cells after 1 hr relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID324552Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 13.2 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID731617Inhibition of beta glucosidase (unknown origin)2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID760612Inhibition of Aspergillus niger amyloglucosidase2013Bioorganic & medicinal chemistry, Aug-15, Volume: 21, Issue:16
(3R,4S,5R,6R,7S)-3,4,5,7-Tetrahydroxyconidine, an azetidine analogue of 6,7-diepicastanospermine and a conformationally constrained d-deoxyaltronojirimycin, from l-arabinose.
AID324579Decrease in FYVE-RFP+ vesicle intensity per cell in human H4 cells after 2 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID335627Inhibition of Aspergillus niger amyloglucosidase at 7 uM by competitive inhibition-based kinetic assay
AID438025Antiviral activity against Dengue virus2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
The medicinal chemistry of dengue fever.
AID1632764Binding affinity to recombinant hexa-histidine-tagged human full-length N-GLY1 catalytic domain expressed in Escherichia coli BL21 (DE3) assessed as change in melting temperature by thermal shift assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Novel small molecule binders of human N-glycanase 1, a key player in the endoplasmic reticulum associated degradation pathway.
AID1632765Binding affinity to recombinant hexa-histidine-tagged human full-length N-GLY1 catalytic domain expressed in Escherichia coli BL21 (DE3) by thermal shift assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Novel small molecule binders of human N-glycanase 1, a key player in the endoplasmic reticulum associated degradation pathway.
AID1251291Inhibition of rice alpha-glucosidase using 10 mM p-nitrophenyl-alpha-D-glucopyranoside as substrate2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Quaternary Indolizidine and Indolizidone Iminosugars as Potential Immunostimulating and Glycosidase Inhibitory Agents: Synthesis, Conformational Analysis, Biological Activity, and Molecular Docking Study.
AID324500Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 13.2 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1799390Btman2A from Article 10.1038/nchembio.81: \\Structural and biochemical evidence for a boat-like transition state in beta-mannosidases.\\2008Nature chemical biology, May, Volume: 4, Issue:5
Structural and biochemical evidence for a boat-like transition state in beta-mannosidases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (351)

TimeframeStudies, This Drug (%)All Drugs %
pre-199079 (22.51)18.7374
1990's155 (44.16)18.2507
2000's81 (23.08)29.6817
2010's31 (8.83)24.3611
2020's5 (1.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.60 (24.57)
Research Supply Index5.90 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.83%)5.53%
Reviews11 (3.04%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other348 (96.13%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]